ArticleJACC. Case reports2026
Bipolar Percutaneous Endocardial Septal Radiofrequency Ablation (Bi-PESA): First-in-Human Application for Hypertrophic Obstructive Cardiomyopathy.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- 2026 Expert Consensus Recommendations on Hypertrophic Cardiomyopathy: A Report of the Task Force of the Taiwan Society of Cardiology.Acta Cardiologica Sinica · 2026Article
- New Insights in the Diagnosis and Treatment of Atrial Fibrillation in Patients with Hypertrophic Obstructive Cardiomyopathy.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany patients with drug-refractory hypertrophic obstructive cardiomyopathy (HOCM) decline or are ineligible for surgical myectomy or alcohol septal ablation. Although conventional unipolar percutaneous endocardial septal radiofrequency ablation is a minimally invasive alternative, its limited lesion depth yields only modest left ventricular outflow tract gradient (LVOTG) relief. Bipolar radiofrequency catheter ablation creates deeper lesions in the treatment of ventricular arrhythmias; however, its role in HOCM remains unreported. FIRST-IN-HUMAN/EARLY REPORTS SUMMARY: We present the first in-human case of combined bipolar ablation and percutaneous endocardial septal radiofrequency ablation (Bi-PESA) in an older patient with drug-refractory HOCM. Ultimately, the patient experienced significant reduction in the LVOTG, translating to significant symptomatic improvement. DISCUSSION: This case suggests Bi-PESA could be a novel, effective, and safe septal reduction option for patients with drug-refractory HOCM. NOVELTY: To our knowledge, this is the first-in-human report of Bi-PESA for HOCM to reduce LVOTG and improve symptoms. TAKE-HOME MESSAGE: Bi-PESA may offer a feasible and potentially preferable alternative for patients with HOCM who decline or are ineligible for surgical myectomy or alcohol septal ablation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.